TY - JOUR
T1 - Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
AU - Ring, Alistair
AU - Karuturi, Meghan
AU - Smyth, Emily Nash
AU - Lokhandwala, Tasneem
AU - Sheffield, Kristin M.
AU - Willey, Joanne
AU - Lunacsek, Orsolya
AU - Sapunar, Francisco
AU - Cui, Zhanglin Lin
AU - Coutinho, Anna
AU - Rybowski, Sarah
N1 - Funding Information:
The authors would like to thank Karan Sharma from Eli Lilly Services India Pvt. Ltd. (funded by Eli Lilly and Company) for providing medical writing and editorial support.
Funding Information:
This study was performed under a research contract between Xcenda LLC and Eli Lilly and Company and was funded by Eli Lilly and Company. Publication for this study, including the journal's Rapid Service and Open Access Fees, was also funded by Eli Lilly and Company.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/5
Y1 - 2023/5
N2 - Introduction: Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in male MBC is lacking. Methods: This analysis was a part of a broader, retrospective study that analyzed electronic medical records and charts of 448 men and women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) MBC who initiated an abemaciclib-containing regimen from January 2017 through September 2019. Data were collected from the Florida Cancer Specialists & Research Institute and the Electronic Medical Office Logistics Health Oncology Warehouse Language™ databases and summarized descriptively. Real-world best response was described: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Results: Data for six male patients with MBC who were treated with abemaciclib in combination with an aromatase inhibitor (AI) or fulvestrant are presented. Four patients were aged ≥ 75 years, and four patients had ≥ 3 metastatic sites, including visceral involvement. Abemaciclib was initiated in/after third-line (≥ 3L) in four patients, and patients had history of treatment with AI (n = 4), chemotherapy (n = 3), and/or prior cyclin-dependent kinase 4 and 6 inhibitors (n = 2) in the metastatic setting. Abemaciclib + fulvestrant was the most common abemaciclib-containing regimen (n = 4). Best response was documented in four patients: 1 each with CR, PR, SD, and PD. Conclusion: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.
AB - Introduction: Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in male MBC is lacking. Methods: This analysis was a part of a broader, retrospective study that analyzed electronic medical records and charts of 448 men and women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) MBC who initiated an abemaciclib-containing regimen from January 2017 through September 2019. Data were collected from the Florida Cancer Specialists & Research Institute and the Electronic Medical Office Logistics Health Oncology Warehouse Language™ databases and summarized descriptively. Real-world best response was described: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Results: Data for six male patients with MBC who were treated with abemaciclib in combination with an aromatase inhibitor (AI) or fulvestrant are presented. Four patients were aged ≥ 75 years, and four patients had ≥ 3 metastatic sites, including visceral involvement. Abemaciclib was initiated in/after third-line (≥ 3L) in four patients, and patients had history of treatment with AI (n = 4), chemotherapy (n = 3), and/or prior cyclin-dependent kinase 4 and 6 inhibitors (n = 2) in the metastatic setting. Abemaciclib + fulvestrant was the most common abemaciclib-containing regimen (n = 4). Best response was documented in four patients: 1 each with CR, PR, SD, and PD. Conclusion: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.
KW - Abemaciclib
KW - Male patients
KW - Metastatic breast cancer
KW - Outcome
KW - Treatment pattern
UR - http://www.scopus.com/inward/record.url?scp=85151353393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151353393&partnerID=8YFLogxK
U2 - 10.1007/s12325-023-02471-8
DO - 10.1007/s12325-023-02471-8
M3 - Article
C2 - 36995468
AN - SCOPUS:85151353393
SN - 0741-238X
VL - 40
SP - 2515
EP - 2523
JO - Advances in Therapy
JF - Advances in Therapy
IS - 5
ER -